MicroRNAs in acute myocardial infarction: Evident value as novel biomarkers?
1Department of Cardiology, West China Hospital of Sichuan University, Chengdu-China
2Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu-China
Anatol J Cardiol 2018; 19(2): 140-147 PubMed ID: 29424735 PMCID: 5864810 DOI: 10.14744/AnatolJCardiol.2017.8124
Full Text PDF

Abstract

Traditional circulating biomarkers play a fundamental role in the diagnosis and prognosis of acute myocardial infarction (AMI). However, they have several limitations. microRNAs (miRs), a class of RNA molecules that do not encode proteins, function directly at the RNA level by inhibiting the translation of messenger RNAs. Due to their significant roles in disease development, they can be used as biomarkers. Accumulating evidence has revealed an attractive role of miRs as biomarkers of AMI and its associated symptoms, including vulnerable atherosclerotic plaques, and their role in disease diagnosis, platelet activation monitoring, and prognostic outcome prediction. This manuscript will highlight the recent updates regarding the involvement of miRs as biomarkers in AMI and emphasize their value in vulnerable atherosclerotic plaque prediction and monitoring of platelet activation.